NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.
Bachem intends a capital increase to accelerate capacity expansion and construction of an additional manufacturing site in Switzerland
Ad hoc announcement pursuant to Art. 53 LR of the Swiss stock exchange SIX
• Call for an Extraordinary General Meeting on October 15, 2021, to create additional authorized share capital.
• Authorization of up to 1 million new shares, representing ca. 7% of currently issued share capital.
• Capital to be used to finance investments in capacity expansion, including an additional manufacturing site in Switzerland.
• Upon completion the capital increase will enhance the trading liquidity of Bachem shares and expand the shareholder base.
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides.
With 50 years of experience and expertise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.
Press release in English
Press release in German
For more information:
Bachem Holding AG
Dr. Daniel Grotzky
Head Group Communications